Navigation Links
Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche
Date:5/25/2011

AUSTIN, Texas, May 25, 2011 /PRNewswire/ -- Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova's biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.

"Achieving this milestone is an example of how pharmaceutical and biotechnology companies can leverage RBM's testing services, databases, and expertise to make real progress," said Craig Benson, President and CEO of RBM. "We appreciate the opportunity to work with a company of Roche's stature and experience to develop a product that both meets Roche's needs and can potentially improve patient outcomes. RBM values this relationship with a company that is leading the way and shares our vision for personalized healthcare"

This project highlights Rules-Based Medicine's Strategic Biomarker Services. RBM consults with our partners to design the best clinical trial, using our comprehensive menu of quantitative immunoassays and decades of expertise in sample type selection, experimental design, and data analysis.

On April 27, 2011, Myriad Genetics (Nasdaq: MYGN) of Salt Lake City, a leader in molecular diagnostics, announced an agreement to acquire Rules-Based Medicine. The transaction is expected to be complete by May 31, 2011. RBM headquarters will remain in Austin, TX and will operate as a wholly owned subsidiary of Myriad Genetics under the name Myriad RBM.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at www.rulesbasedmedicine.com.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
2. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
3. Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
4. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
5. Particle trap paves way for personalized medicine
6. ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
7. Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine
8. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
9. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
10. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine
11. Aesthetic Plastic Surgery and Anti Aging Medicine Symposium Features New Developments in the Science of Stem Cells and Fat Grafting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017 Research and Markets has ... Markets" report to their offering. ... The ... parts, delivery plasmids, chassis organisms, synthetic cells, production systems), ... editing, bioinformatics and specialty media) and enabled technologies (biofuels, ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... development and sale of advanced technology solutions and products ... today announced the addition of new cohorts of PDX ... new models will expand Champions, product line in hepatocellular ... neck cancer, AML, and non-small cell lung cancer (including ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
Breaking Biology Technology:
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/25/2017)... 2017 The Elements of Enterprise Information Security ... comprised of a comprehensive set of business processes ... digital identities and providing a secured and documented ... significant number of programs opted by enterprises to ... optimizing processes and changing policies. However, there are ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):